F5006
2-Fluoro-2-deoxy-D-glucose
glycosylation inhibitor, glucose analog
Sign Into View Organizational & Contract Pricing
All Photos(2)
2-Deoxy-2-fluoro-D-glucose, FDG, 2-Deoxy-2-fluoro-D-glucose
C6H11FO5
Recommended Products
Quality Level
storage temp.
2-8°C
SMILES string
OCC1OC(O)C(F)C(O)C1O
InChI
1S/C6H11FO5/c7-3-5(10)4(9)2(1-8)12-6(3)11/h2-6,8-11H,1H2
InChI key
ZCXUVYAZINUVJD-UHFFFAOYSA-N
Looking for similar products? Visit Product Comparison Guide
Related Categories
General description
2-Fluoro-2-deoxy-D-glucose is non-toxic and a structural analog of glucose, significantly inhibiting glycosylation. As a glucose analog, uptake of 2-Fluoro-2-deoxy-D-glucose is rapid in brain and heart cells.
2-Fluoro-2-deoxy-D-glucose can be taken up by cells but does not undergo metabolic glycolysis.
2-Fluoro-2-deoxy-D-glucose can be taken up by cells but does not undergo metabolic glycolysis.
Application
2-Fluoro-2-deoxy-D-glucose is used as a tracer for rapid tumor detection. It is used as a glucose analog to study glucose uptake in mice with radiation and burn injuries. Oncology therapy studies use FDG in combination with PET (Positron Emission Topography)
Biochem/physiol Actions
Glucose analog that inhibits cellular glycosylation.
Signal Word
Warning
Hazard Statements
Precautionary Statements
Hazard Classifications
Eye Irrit. 2 - Skin Irrit. 2 - STOT SE 3
Target Organs
Respiratory system
WGK
WGK 3
Flash Point(F)
Not applicable
Flash Point(C)
Not applicable
Personal Protective Equipment
dust mask type N95 (US), Eyeshields, Gloves
Certificates of Analysis (COA)
Search for Certificates of Analysis (COA) by entering the products Lot/Batch Number. Lot and Batch Numbers can be found on a product’s label following the words ‘Lot’ or ‘Batch’.
Already Own This Product?
Find documentation for the products that you have recently purchased in the Document Library.
European journal of nuclear medicine, 27(6), 731-743 (2000-07-20)
[18F]-2-fluoro-2-deoxy-D-glucose positron emission tomography (FDG PET) is considered a valuable tool in the diagnosis and staging of cancer. In addition, it seems promising as a technique to monitor response to therapy. Progress is hampered, however, by the fact that various
Journal of nuclear medicine : official publication, Society of Nuclear Medicine, 55(1), 37-42 (2013-11-23)
The number of studies in the literature involving quantification of the metabolic heterogeneity seen in (18)F-FDG PET images has increased sharply over recent years. We hypothesized that inclusion of very small regions of interest as unique data points will have
American heart journal, 166(6), 990-998 (2013-11-26)
The presence of subclinical atherosclerosis is a likely predictor of cardiovascular events; however, factors associated with the early stages and progression of atherosclerosis are poorly defined. The PESA study examines the presence of subclinical atherosclerosis by means of noninvasive imaging
Biochimica et biophysica acta, 696(3), 285-289 (1982-03-29)
Tunicamycin, 2-deoxy-D-glucose and 2-deoxy-2-fluoro-D-glucose inhibit dimethyl sulfoxide-induced differentiation of Friend cells. This inhibition, characterized by inhibition of hemoglobin synthesis, is accompanied by a specific inhibition of protein glycosylation. The results of cloning experiments indicate that this inhibition specifically affects cells
Journal of nuclear medicine : official publication, Society of Nuclear Medicine, 21(7), 670-675 (1980-07-01)
Rapid uptake of F-18 FDG was observed in a variety of transplanted and spontaneous tumors in animals. The tumor uptake reached a peak by 30 min and remained relatively constant up to 60 min, with a very slow wash-out of
Our team of scientists has experience in all areas of research including Life Science, Material Science, Chemical Synthesis, Chromatography, Analytical and many others.
Contact Technical Service